<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04630080</url>
  </required_header>
  <id_info>
    <org_study_id>SYM013</org_study_id>
    <nct_id>NCT04630080</nct_id>
  </id_info>
  <brief_title>Alopecia Prevention Scalp Cooling in Chinese Breast Cancer Patients</brief_title>
  <official_title>Scalp Cooling Study for the Prevention of Chemotherapy-induced Alopecia in Chinese Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Orbis Paxman Hair Loss Prevention System is a new equipment introduced to Hong Kong in&#xD;
      2017. Although this device has been widely used in the United States, Europe and Australia,&#xD;
      acceptability, efficacy and safety data in Chinese have not yet been available. The objective&#xD;
      of this prospective study is to collect clinical data in Chinese patients using the Orbis&#xD;
      Paxman Hair Loss Prevention System to prevent chemotherapy-induced alopecia.&#xD;
&#xD;
      This project seeks to demonstrate that the Orbis Paxman Hair Loss Prevention System is safe&#xD;
      and effective in reducing chemotherapy-induced alopecia in woman with breast cancer&#xD;
      undergoing neoadjuvant or adjuvant chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The success rate of scalp cooling in preventing chemotherapy-induced alopecia</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of preceived hair preservation during and after completion of chemotherapy</measure>
    <time_frame>2 years</time_frame>
    <description>It will be assessed by study tool ALOPECIA ASSESSMENT BY PATIENT AND WIG USE FORM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The quality of life during and after completion of chemotherapy</measure>
    <time_frame>2 years</time_frame>
    <description>It will be assessed by study tool EORTC QLQ-30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The disease site specific quality of life during and after completion of chemotherapy</measure>
    <time_frame>2 years</time_frame>
    <description>It will be assessed by study tool EORTC QLQ - BR23</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of treatment-emergent adverse events of scalp cooling</measure>
    <time_frame>2 years</time_frame>
    <description>It will be assessed by COMFORT SCALE FORM.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Scalp Cooling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Scalp cooling</intervention_name>
    <description>Scalp cooling is a physical method to reduce chemotherapy-induced alopecia</description>
    <arm_group_label>Scalp Cooling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        i) New diagnosis of breast cancer stage I-III&#xD;
&#xD;
        ii) Chinese ethnicity&#xD;
&#xD;
        iii) ECOG 0-1&#xD;
&#xD;
        iii) Planning to undergo neoadjuvant or adjuvant chemotherapy with curative intent&#xD;
&#xD;
        iv) Chemotherapy must be planned for at least 4 cycles of full-dose anthracycline and/or&#xD;
        taxane based chemotherapy regimen,&#xD;
&#xD;
          1. Defined as one of the following regimens:&#xD;
&#xD;
               -  Adriamycin 60 mg/m2 with cyclophosphamide 600 mg/m2 for 4 cycles (AC) &gt;&#xD;
                  5-Fluorouracil 500 mg/m2, Epirubicin 100mg/m2, and cyclophosphamide 500 mg/m2 for&#xD;
                  3 cycles, followed by Docetaxel 100 mg/m2 for 3 cycles (FEC-D)&#xD;
&#xD;
               -  AC x 4 cycles, followed by Docetaxel 100 mg/m2 for 4 cycles (AC-D)&#xD;
&#xD;
               -  AC x 4 cycles, followed by Paclitaxel 175 mg/m2 for 4 cycles (AC-P)&#xD;
&#xD;
               -  Docetaxel 75 mg/m2 with cyclophosphamide 600 mg/m2 for 4-6 cycles (DC)&#xD;
&#xD;
               -  Docetaxel 75 mg/m2 with carboplatin AUC of 5-6 for 4-6 cycles (DCb)&#xD;
&#xD;
          2. Concurrent trastuzumab and/or pertuzumab at standard doses is allowed.&#xD;
&#xD;
          3. Administration of chemotherapy on a dose dense schedule with GCSF is allowed.&#xD;
&#xD;
        v) Adequate organ functions vi) Normal thyroid stimulating hormone vii) Subjects with&#xD;
        history of diabetes must have acceptable HBA1c on study entry viii) Subjects who provide&#xD;
        consent and are mentally competent and able to fill in study questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        i) Subjects with any other concurrent malignancy including hematological malignancies (i.e.&#xD;
        leukemia or lymphoma)&#xD;
&#xD;
        ii) Subjects with cold agglutinin disease or cold urticaria&#xD;
&#xD;
        iii) Age â‰¥ 70 years&#xD;
&#xD;
        iv) Personal history of migraines, cluster or tension headaches as defined as actual&#xD;
        medical diagnosis by a physician and/ or prescribed medications. If personal history of&#xD;
        migraines was related to a past medical problem that is now resolved, subject may go on&#xD;
        study at the discretion of the Principal Investigator.&#xD;
&#xD;
        v) Elevated liver enzymes or bilirubin defined as 3 times the upper limits of normal&#xD;
&#xD;
        vi) Serum Albumin &lt; 3.0&#xD;
&#xD;
        vii) Subjects with anemia (defined as a hemoglobin &lt; 10)&#xD;
&#xD;
        viii) Subjects who have lichen planus or lupus, or other dermatological conditions&#xD;
        involving scalp&#xD;
&#xD;
        ix) Subjects who are underweight (defined as a BMI &lt; 18.5)&#xD;
&#xD;
        x) Subjects who have had previous chemotherapy exposure&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winnie Yeo, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Oncology, Prince of Wales Hosptial</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Winnie Yeo, MD, FRCP</last_name>
    <phone>3505 2118</phone>
    <email>winnie@clo.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dong Lai, RN</last_name>
    <phone>3505 1138</phone>
    <email>dong@clo.cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winnie Yeo, MD, FHKCP</last_name>
      <phone>3505 2118</phone>
      <email>winne@cloc.uhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Dong Lai, RN</last_name>
      <phone>3505 1138</phone>
      <email>dong@clo.cuhk.edu.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Winnie Yeo</investigator_full_name>
    <investigator_title>Professor, Department of Clinical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Alopecia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

